Adelheid Cerwenka

Title: Adelheid Cerwenka: Innovator in Immunotherapy

Introduction

Adelheid Cerwenka is a prominent inventor based in Heidelberg, Germany. She has made significant contributions to the field of immunotherapy, particularly in the development of novel therapeutic antibodies. With a total of 2 patents, her work focuses on advancing cancer treatment and diagnostic methods.

Latest Patents

Cerwenka's latest patents include a combination of an anti-CD16A antibody with a cytokine. This invention relates to an anti-CD16A antigen binding protein designed for use in NK cell-based immunotherapy. The anti-CD16A antigen binding protein is intended to be administered intermittently and in combination with a cytokine. In certain embodiments, the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody. Another significant patent is for a B7-H6 therapeutically active monoclonal antibody against the B7-H6 polypeptide. This invention is concerned with diagnostic methods and means, specifically relating to an antibody that binds to a portion of the extracellular domain of the B7-H6 polypeptide. The antibody is provided for use in the treatment or diagnosis of cancer or inflammatory diseases.

Career Highlights

Throughout her career, Cerwenka has worked with notable organizations, including Affimed GmbH and Deutsches Krebsforschungszentrum. Her expertise in immunotherapy has positioned her as a key figure in the development of innovative treatments for cancer.

Collaborations

Cerwenka has collaborated with esteemed colleagues such as Joachim Koch and Martin Treder. These partnerships have further enhanced her research and contributions to the field.

Conclusion

Adelheid Cerwenka's work in immunotherapy exemplifies her commitment to advancing medical science. Her innovative patents and collaborations highlight her significant impact on cancer treatment and diagnostics.